Study of Jaktinib In Patients With Myelofibrosis Who Were Relapsed or Refractory of Ruxolitinib Treatment.

Phase 2 Completed 34 enrolled Suzhou Zelgen Biopharmaceuticals Co.,Ltd

NaSingle-groupOpen-labelTreatment

Summary

This was a phase 2, single-arm, open-label, non-randomised, multicentre, study to evaluate the efficacy and safety of Jaktinib in patients with myelofibrosis who were relapsed or refractory of ruxolitinib treatment.

Timeline

Start: 2021-07-28
Primary completion: 2022-11-01
Completion: 2022-11-01

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Jaktinib	Unknown	100 mg	Oral

Study of Jaktinib In Patients With Myelofibrosis Who Were Relapsed or Refractory of Ruxolitinib Treatment.

Summary

Timeline

Drugs

Indications